A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
A five-year-old boy who received the world's most expensive drug as a baby has made "incredible progress" and can walk ...
By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial ...
Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...
U.K. biotech Ikarovec has teamed up with VectorBuilder to work on an eye disease gene therapy that could be administered in a ...
As CRISPR moves from lab success to real-world medicine, 2026 will test whether these revolutionary gene-editing therapies ...
Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...
This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...
A baby born with a rare genetic disorder has taken his first steps after receiving a groundbreaking, personalized gene editing treatment at CHOP.
A 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment was released from the hospital this week.
AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.
A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback